B of A Securities Maintains Neutral on Arcus Biosciences, Raises Price Target to $26
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Jason Zemansky maintains Arcus Biosciences (NYSE:RCUS) with a Neutral and raises the price target from $17 to $26.
B of A Securities analyst Jason Zemansky maintains Arcus Biosciences (NYSE:RCUS) with a Neutral and raises the price target from $17 to $26.